Sanofi wants to earn the rep for be­ing the hare in drug R&D. But that darn tor­toise keeps stick­ing its head out

This is an im­por­tant day for Sanofi.

For years now it’s been forced to con­sid­er deep doubts sur­round­ing its abil­i­ty to ex­e­cute in R&D, with a long his­to­ry of slow-foot­ed clin­i­cal ad­vances and a weak in-house pipeline. Its cut­ting-edge in­no­va­tion projects came from Re­gen­eron, which it’s been sep­a­rat­ing from. And to­day, dur­ing R&D day, Sanofi CEO Paul Hud­son as well as R&D chief John Reed hope to leave that all be­hind with a force­ful pre­sen­ta­tion on the phar­ma gi­ant’s new­found nim­ble­ness and ca­pac­i­ty to build an ex­cit­ing late-stage pipeline with sev­er­al top projects in hand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER